Literature DB >> 28427852

Circumferential pulmonary vein isolation with second-generation multipolar catheter in patients with paroxysmal or persistent atrial fibrillation: Procedural and one-year follow-up results.

Stefan G Spitzer1, Patrick Leitz2, Anke Langbein1, Laszlo Karolyi1, Frank Scharfe1, Thomas Weinmann1, Carola Rämmler1, Christian Pott3, Gerold Mönnig3, Lars Eckardt3.   

Abstract

BACKGROUND: There is a lack of procedural and follow-up data on pulmonary vein isolation (PVI) with the second-generation pulmonary vein ablation catheter® (PVAC Gold) in patients with atrial fibrillation (AF). This study provides data on PVI procedures and 1-year follow-up results with PVAC Gold in patients with AF treated in clinical practice. METHODS AND
RESULTS: Three hundred and eighty four patients with documented symptomatic paroxysmal (n=198) or persistent (n=186) AF were included in a non-randomized prospectively designed database. Patients were enrolled consecutively at 2 high-volume centers. Procedural as well as 1year follow-up data were systematically analyzed. Average procedure times±standard deviations were 94±23min and 97±23min, respectively, in patients with paroxysmal and persistent AF. Average fluoroscopy times were 14.7±5.4min and 15.2±5.6min and total application times 18.1±5.0min and 18.8±5.2min, respectively, in the 2 patient cohorts. At 12months, 70.7% (70/99) and 61.9% (70/113) of patients with paroxysmal and persistent AF, respectively, were free from AF. Four early complications occurred. In the group with persistent AF, 1 posterior cerebral infarction occurred 2days after the procedure during initiation of anticoagulation. There was no phrenic nerve palsy or esophageal injury associated with the procedures. No thromboembolic events were recorded during follow-up.
CONCLUSIONS: In patients with paroxysmal or persistent AF, second generation multi-electrode-phased radiofrequency ablation delivers favorable mid-term PVI success rates with few procedure-related or follow-up complications.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical practice; Paroxysmal atrial fibrillation; Persistent atrial fibrillation; Phased radiofrequency ablation; Safety

Mesh:

Year:  2017        PMID: 28427852     DOI: 10.1016/j.ijcard.2017.04.035

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

Review 1.  The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications.

Authors:  Fehmi Keçe; Katja Zeppenfeld; Serge A Trines
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

2.  Clinical outcomes of AF patients treated with the first and second-generation of circular mapping and ablation catheter: insights from a real world multicenter experience.

Authors:  Giovanni Rovaris; Paolo De Filippo; Francesco Laurenzi; Gabriele Zanotto; Nicola Bottoni; Mattia Pozzi; Fabrizio Giofrè; Piergiuseppe De Girolamo; Emanuela Visentin; Elena Piazzi; Paola Ferrari
Journal:  J Interv Card Electrophysiol       Date:  2017-09-05       Impact factor: 1.900

3.  Is the time of atrial fibrillation recurrence after cryoballoon ablation of paroxysmal atrial fibrillation influenced by the pattern of PV reconnections?

Authors:  Marcus Wieczorek; Kiarash Sassani; Reinhard Hoeltgen
Journal:  J Interv Card Electrophysiol       Date:  2020-07-03       Impact factor: 1.900

4.  Pulmonary vein isolation using second-generation single-shot devices: not all the same?

Authors:  Philipp Seidl; Frank Steinborn; Lisa Costello-Boerrigter; Ralf Surber; Paul C Schulze; Christine Böttcher; Andreas Sommermeier; Violeta Mattea; Roland Simeoni; Frank Michael Malur; Harald Lapp; Anja Schade
Journal:  J Interv Card Electrophysiol       Date:  2020-05-15       Impact factor: 1.900

5.  Comparison of pulmonary vein reconnection patterns after multielectrode phased radiofrequency- and cryoballoon ablation of atrial fibrillation.

Authors:  Marcus Wieczorek; Kiarash Sassani; Reinhard Hoeltgen
Journal:  BMC Cardiovasc Disord       Date:  2020-04-23       Impact factor: 2.298

6.  Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real-world data on safety and efficacy.

Authors:  Kevin Willy; Kristina Wasmer; Dirk G Dechering; Julia Köbe; Philipp S Lange; Nils Bögeholz; Christian Ellermann; Florian Reinke; Gerrit Frommeyer; Lars Eckardt
Journal:  Clin Cardiol       Date:  2020-10-19       Impact factor: 2.882

7.  Acute success and safety of the second-generation PVAC GOLD phased RF ablation catheter for atrial fibrillation.

Authors:  M N Klaver; L I S Wintgens; M C E F Wijffels; J C Balt; V F van Dijk; A Alipour; S M Chaldoupi; R Derksen; L V A Boersma
Journal:  J Interv Card Electrophysiol       Date:  2020-04-06       Impact factor: 1.900

8.  Correlation of pulmonary vein reconnection patterns after cryoballoon and duty-cycled ablation of atrial fibrillation with the time of arrhythmia recurrence.

Authors:  Marcus Wieczorek; Kiarash Sassani; Reinhard Hoeltgen
Journal:  J Arrhythm       Date:  2020-09-24

9.  The Incidence, Electrophysiological Characteristics and Ablation Outcome of Left Atrial Tachycardias after Pulmonary Vein Isolation Using Three Different Ablation Technologies.

Authors:  Patrick Leitz; Kristina Wasmer; Christian Andresen; Fatih Güner; Julia Köbe; Benjamin Rath; Florian Reinke; Julian Wolfes; Philipp S Lange; Christian Ellermann; Gerrit Frommeyer; Lars Eckardt
Journal:  J Cardiovasc Dev Dis       Date:  2022-02-03

10.  Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter GOLD duty-cycled phased radiofrequency ablation catheter: quality of life and 12-month efficacy results from the GOLD Atrial Fibrillation Registry.

Authors:  Lucas Boersma; Edward Koźluk; Giampiero Maglia; João de Sousa; Olaf Grebe; Lars Eckardt; Robert B Hokanson; Lauren A Hemingway; Ekaterina Ostern; Hyoung-Seob Park; Giovanni Rovaris; Fernando Arribas; Christoph Scharf; Zoltán Csanádi; Ángel Arenal; Francesco Laurenzi; Martijn Klaver; Andreas Goette
Journal:  Europace       Date:  2020-06-01       Impact factor: 5.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.